US20260108581A1 Microsphere Carnosine for Neurodegenerative Diseases
Summary
USPTO published patent application US20260108581A1, filed March 4, 2025, titled 'Compositions and Methods for Microsphere Delivery of Carnosine for Treatment of Neurodegenerative Diseases and Disorders.' Inventors Spencer Bouhadir and Jacob J. Miguel seek protection for microsphere-based carnosine delivery compositions intended for treatment of neurodegenerative diseases or conditions. As a published patent application, this document represents a pre-grant publication stage and does not confer any enforceable patent rights or regulatory obligations on third parties at this time.
“COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108581A1 for compositions and methods of microsphere delivery of carnosine for treatment of neurodegenerative diseases and disorders. The application, filed March 4, 2025 by inventors Spencer Bouhadir and Jacob J. Miguel, discloses carnosine loaded in microsphere formulations as a drug delivery vehicle for neuroprotective applications.
Affected parties in the pharmaceutical and biotechnology sectors should monitor the prosecution of this application for potential freedom-to-operate implications, particularly if developing carnosine-based or microsphere-based neurodegenerative disease treatments. Publication of a patent application does not create immediate compliance obligations but may signal competitive研发 activity in the targeted therapeutic area. Third parties may file third-party observations under 37 CFR 1.99 during the pendency of the application.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPOSITIONS AND METHODS FOR MICROSPHERE DELIVERY OF CARNOSINE FOR TREATMENT OF NEURODEGENERATIVE DISEASES AND DISORDERS
Application US20260108581A1 Kind: A1 Apr 23, 2026
Inventors
Spencer Bouhadir, Jacob J. Miguel
Abstract
The present disclosure provides, inter alia, compositions and methods for microsphere delivery of carnosine for treatment of neurodegenerative diseases or conditions.
CPC Classifications
A61K 38/05 A61K 9/0019 A61K 9/5026 A61K 9/5031 A61K 9/5036 A61P 25/16
Filing Date
2025-03-04
Application No.
19070270
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.